



Tanvex has reached a Patent License Agreement with Amgen

March 02, 2021

Tanvex announced that the company has reached a license agreement with Amgen for a patent in Canada that relates to filgrastim (Canadian patent 1,341,537). Terms of the license are not disclosed.

TX01 is a proposed biosimilar of filgrastim (Neupogen®). Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) analog.

About Tanvex

Tanvex BioPharma, Inc. (TWSE: 6541) is a biopharmaceutical company focused on the biosimilar market. The Company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, San Diego, CA, and Taipei, Taiwan. Tanvex is publicly traded on the Taiwan Stock Exchange.